




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445, C07D 401/02, 401/14, 409/02		A1	(11) International Publication Number: WO 95/13069
			(43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/12816		(72) Inventors; and	
(22) International Filing Date: 7 November 1994 (07.11.94)		(75) Inventors/Applicants (for US only): MORRIELLO, Gregori, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PATCHETT, Arthur, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). YANG, Lihu [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). CHEN, Meng, H. [-/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). NARGUND, Ravi [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(30) Priority Data:		(74) Common Representative: MERCK & CO., INC. ; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
149,441	9 November 1993 (09.11.93)	US	
165,149	10 December 1993 (10.12.93)	US	
173,449	23 December 1993 (23.12.93)	US	
323,994	17 October 1994 (17.10.94)	US	
323,998	17 October 1994 (17.10.94)	US	
323,988	17 October 1994 (17.10.94)	US	
(60) Parent Applications or Grants		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(63) Related by Continuation		Published	
US	323,994 (CIP)	With international search report.	
Filed on	17 October 1994 (17.10.94)		
US	323,998 (CIP)		
Filed on	17 October 1994 (17.10.94)		
US	323,988 (CIP)		
Filed on	17 October 1994 (17.10.94)		
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			


(54) Title: PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE

(57) Abstract

The present invention is directed to certain piperidine, pyrrolidine, and hexahydro-1H-azepine compounds of general structural formula (I) wherein R₁, R₃, R₄, R₅, A, W, X, Y, and n are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.




- 133 -

TABLE AIV: ADDITIONAL EXAMPLES

Product


entry	Intermediate (QH)	Product
	MF	MF
	FAB-MS (M+1)	FAB-MS (M+1)
1		d1: C ₃₁ H ₄₀ N ₄ O ₄ 533
2		d2: C ₃₁ H ₄₀ N ₄ O ₄ 533
3		mixture of diastereomers C ₃₂ H ₄₂ N ₄ O ₄ 547

Likewise the compounds shown below are prepared according to Example A12 by alkylating with 2-picoly chloride or 4-bromomethylthiazole to give the following intermediates:




- 134 -

which may then be reacted with Intermediates 1 or 2 to give the following compounds respectively:




EXAMPLE A13



- 135 -

Step A:

5



10 To a stirred solution of dl-2-pipecolamidoethanol (100 mg, (1.16 mmol), HOBT (78.38 mg, 1.16 mmol) and Intermediate 1 (226.12 mg, 1.16 mmol) in dichloromethane (3ml) at ambient temperature was added 4-methyl morpholine (63.8 ml, (1.16 mmol)). The mixture was cooled to 0° C and to which was added EDC (222.3 mg, 2.32 mmol). The reaction mixture was stirred at room temperature for 16 h. After
 15 evaporation, the residue was partitioned in ethyl acetate and 1N hydrochloric acid. The organic layer was washed with saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to an oily foam which was purified by preparative tlc (acetone/chloroform: 3/7) to give 91 mg of the product (R_f = 0.45).
 20 CI-MS : calc. for $C_{28}H_{41}N_5O_6$: 543 ; Found 544(M+H)
 ¹H NMR (400 MHz, $CDCl_3$): δ 8.35 (br.s, 1H), 7.57 & 7.55 (2s, 1H), 7.35, 7.33, (2s, 2H), 7.17 (t, J = 6.95Hz, 1H), 7.15-7.07 (m, 3H), 7.03 (distorted t, J = 4.95 Hz, 1H), 5.16 (d, J =4.68 Hz, 1H), 4.94 (m, 2H), 3.65 (m, 2H), 3.55-3.10 (m, 5H), 2.9-2.62 (m, 4H), 2.3-2.2 (m, 1H), 1.43, 1.46
 25 and 1.41 (3 s, total 15H), 1.00 (m, 1H), 0.83 (m, 1H).

Step B:

30

